Drugs / NGM707
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04913337 | Jun 2021 → Feb 2025 | breast cancer, cholangiocarcinoma, colorectal cancer, endocervical carcinoma +10 | NGM Biopharmaceuticals, Inc | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07511972 | Nov 2023 → Dec 2024 | — | NGM Biopharmaceuticals, Inc | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGM707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07511972 ↗ |
| Route | Intravenous | “NGM707 is given intravenously (IV)” NCT04913337 ↗ |